Vantage logo

Big pharma spinouts grow up

Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.

Vantage logo

Amarin falls at obvious hurdle

Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.